Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEVEN G WAGUESPACK and CAMILO JIMENEZ.
STEVEN G WAGUESPACK
Connection Strength
4.780
CAMILO JIMENEZ
  1. TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.
    View in: PubMed
    Score: 0.890
  2. Functional imaging for pheochromocytoma-paraganglioma: a step closer to understanding its place in clinical practice. Endocrine. 2015 Sep; 50(1):6-8.
    View in: PubMed
    Score: 0.518
  3. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010 May; 95(5):2023-37.
    View in: PubMed
    Score: 0.359
  4. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb; 94(2):386-91.
    View in: PubMed
    Score: 0.328
  5. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 2024 Dec 04.
    View in: PubMed
    Score: 0.249
  6. Reply to the Letter to the Editor Concerning Metabolic and Pharma-cological Interactions of 131I-MIBG. Clin Nucl Med. 2024 Oct 10.
    View in: PubMed
    Score: 0.247
  7. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
    View in: PubMed
    Score: 0.239
  8. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019 03; 7(3):213-220.
    View in: PubMed
    Score: 0.166
  9. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
    View in: PubMed
    Score: 0.114
  10. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013 Apr; 98(4):1492-7.
    View in: PubMed
    Score: 0.110
  11. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012 Jun 01; 118(11):2804-12.
    View in: PubMed
    Score: 0.100
  12. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol. 2011 Aug 23; 7(10):596-607.
    View in: PubMed
    Score: 0.099
  13. Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication. J Clin Oncol. 2011 Jun 01; 29(16):e462-4.
    View in: PubMed
    Score: 0.096
  14. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar; 96(3):717-25.
    View in: PubMed
    Score: 0.095
  15. A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. Cancer Invest. 2008 Jul; 26(6):642-6.
    View in: PubMed
    Score: 0.080
  16. Author Correction: International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol. 2024 Dec; 20(12):760.
    View in: PubMed
    Score: 0.062
  17. SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
    View in: PubMed
    Score: 0.062
  18. International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol. 2024 Dec; 20(12):729-748.
    View in: PubMed
    Score: 0.061
  19. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist. 2024 Jul 05; 29(7):575-580.
    View in: PubMed
    Score: 0.061
  20. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30.
    View in: PubMed
    Score: 0.058
  21. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
    View in: PubMed
    Score: 0.052
  22. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery. 2022 08; 172(2):559-566.
    View in: PubMed
    Score: 0.052
  23. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
    View in: PubMed
    Score: 0.045
  24. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986.
    View in: PubMed
    Score: 0.043
  25. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg. 2018 07; 268(1):172-178.
    View in: PubMed
    Score: 0.040
  26. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
    View in: PubMed
    Score: 0.039
  27. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
    View in: PubMed
    Score: 0.035
  28. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.035
  29. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467.
    View in: PubMed
    Score: 0.035
  30. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9.
    View in: PubMed
    Score: 0.033
  31. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81.
    View in: PubMed
    Score: 0.031
  32. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
    View in: PubMed
    Score: 0.030
  33. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
    View in: PubMed
    Score: 0.030
  34. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
    View in: PubMed
    Score: 0.030
  35. Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone-dependent Cushing?s syndrome. Surgery. 2013 Dec; 154(6):1174-83; discussion 1183-4.
    View in: PubMed
    Score: 0.029
  36. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899.
    View in: PubMed
    Score: 0.029
  37. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf). 2014 Mar; 80(3):342-7.
    View in: PubMed
    Score: 0.029
  38. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
    View in: PubMed
    Score: 0.027
  39. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013 Jan; 98(1):192-7.
    View in: PubMed
    Score: 0.027
  40. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012 Nov; 97(11):4040-50.
    View in: PubMed
    Score: 0.027
  41. Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract. 2011 Sep-Oct; 17(5):717-26.
    View in: PubMed
    Score: 0.025
  42. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
    View in: PubMed
    Score: 0.024
  43. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011 Feb; 21(2):189-92.
    View in: PubMed
    Score: 0.024
  44. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.